 Autologous CD133 bone marrow progenitor cells will be harvested from study subjects at the time of CABG, processed and then injected into patients myocardium prior to completion of CABG surgery. The test material consists of autologous CD133 cells. Since intra-myocardial injections per se could stimulate neovascularization, control group patients will receive a placebo injection of carrier solution. Control subjects will thus have an identical procedure to those randomized to autologous CD133 cell injections. 